It’s in the heart of Marseille, a land of research for over 40 years, that we’re taking action for tomorrow’s immunology, research excellence and France’s international influence.
Because Marseille immunotherapy biocluster is at the heart of a new era, in which immunology – a still little-known field – is proving to be a promising response to the crises shaking our society.
Our mission is clear: to push back the frontiers of science and health by contributing to the emergence of new therapies for the benefit of patients.
Our approach is solid: it is rooted in the deep trust we share with the academic world, the hospital world, the authorities, and our industrial and economic partners, from start-ups to pharmaceutical companies.
This powerful virtuous circle enables us to promote and propel a strong culture of innovation in France and abroad.
Our pragmatic approach, rooted in a results-oriented culture, is developing technologies and bringing about discoveries that will change the lives of patients in Marseille and around the world.
We don’t just dream about the future; we act.
We act for each and every one of our patients.
We are acting for the excellence of French research,
We are acting for the immunology of tomorrow.
Making Marseille
an international center
in immunology
MIB aims to position Marseille as a global center of excellence in the field of immunology.
Developing innovative therapies
The biocluster facilitates the rapid transfer of scientific and technological advances for the benefit of patients awaiting therapeutic strategies.
Expanding public-private partnerships
MIB fosters collaboration between the public and private sectors to encourage innovation and the development of new therapies.
Developing and strengthening our appeal
By accelerating innovation and technology transfer within its ecosystem, MIB strengthens the region's economic competitiveness and contributes to France's economic and scientific sovereignty.
Contributing to France's health sovereignty strategy
MIB will contribute to strengthening France's healthcare sovereignty, by stimulating innovation with ambitious 10-year targets: 5 phase 2/3 antibody candidates, 3 approved niche antibodies and 1 blockbuster drug.
Bringing together the best players in immunology
MIB will act as a reference hub, bringing together various players such as industry, research organizations, healthcare professionals, training institutions, start-ups and technology transfer professionals. It will act as a one-stop shop to foster collaboration and innovation.
01
MIB aims to position Marseille as a global center of excellence in the field of immunology.
02
The biocluster facilitates the rapid transfer of scientific and technological advances for the benefit of patients awaiting therapeutic strategies.
03
MIB fosters collaboration between the public and private sectors to encourage innovation and the development of new therapies.
04
By accelerating innovation and technology transfer within its ecosystem, MIB strengthens the region’s economic competitiveness and contributes to France’s economic and scientific sovereignty.
05
MIB will contribute to strengthening France’s healthcare sovereignty, by stimulating innovation with ambitious 10-year targets: 5 phase 2/3 antibody candidates, 3 approved niche antibodies and 1 blockbuster drug.
06
MIB will act as a reference hub, bringing together various players such as industry, research organizations, healthcare professionals, training institutions, start-ups and technology transfer professionals. It will act as a one-stop shop to foster collaboration and innovation.
France’s research reputation
Local economic benefits
Capturing new investment
Positioning MIB as a key immunology hub
Accélération de la recherche en immunologie
Accelerating research in immunology
Capturing new investment
Improving
patient care
Better access to care